Db289 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
65 | Primary immunodeficiency | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00803933 (ClinicalTrials.gov) | February 2003 | 4/12/2008 | Trial of DB289 for the Treatment of Stage I African Trypanosomiasis | Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis | African Trypanosomiasis | Drug: DB289;Drug: Pentamidine | Immtech Pharmaceuticals, Inc | Bill and Melinda Gates Foundation | Completed | 15 Years | 50 Years | Both | 111 | Phase 2 | Congo |
2 | NCT00802594 (ClinicalTrials.gov) | August 2001 | 3/12/2008 | A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis | Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis | Trypanosomiasis, African | Drug: DB289 | Immtech Pharmaceuticals, Inc | Bill and Melinda Gates Foundation | Completed | 16 Years | N/A | Both | 30 | Phase 2 | Angola;Congo |